OMEROS CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Omeros Corp's (NASDAQ:OMER) VP of Finance, David Borges, sold 10,906 shares for $206,804 after exercising options. Shares were sold at $18.95-$19.10, with options exercised at $2.94-$3.93. Omeros reported Q2 earnings of $0.02 per share, beating estimates, and revenue of $28.5M, also exceeding forecasts, driven by its drug YARTEMLEA.
Cable Thomas J. sold 15,000 shares of OMEROS CORP (OMER) at $18.45 ($0.28M total) on 2026-08-20.
Omeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.
Over the past 7 days, alphai's AI scored 1 news story mentioning OMER (OMEROS CORP). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent OMER coverage spans earnings, market movers and financial news.
In the last 30 days, OMER insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($568K). The most active reporter was Borges David J., VP, Finance & CAO, with 3 filings. 75% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal limited confidence, but size is modest for a mid‑cap biotech.
A modest insider sale by a director may signal slight concern but the amount is small relative to float.
Strong sales growth and debt reduction may boost OMER price, while positive cash flow supports further commercialization.
Profitability turnaround plus buyback and governance changes can support near-term sentiment, but the article flags ongoing single-product concentration risk.
Near-term trading focus is on reimbursement timing (J-code effective July 1, NTAP starting Oct 1) and Europe regulatory path after a negative CHMP opinion.
alphai scores every news story that mentions OMER with an AI model for sentiment and relevance, and aggregates insider trades from OMEROS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Omeros Corp's (NASDAQ:OMER) VP of Finance, David Borges, sold 10,906 shares for $206,804 after exercising options. Shares were sold at $18.95-$19.10, with options exercised at $2.94-$3.93. Omeros reported Q2 earnings of $0.02 per share, beating estimates, and revenue of $28.5M, also exceeding forecasts, driven by its drug YARTEMLEA.
2 min readCable Thomas J. sold 15,000 shares of OMEROS CORP (OMER) at $18.45 ($0.28M total) on 2026-08-20.
1 min readOmeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.
3 min readOmeros (OMER) reported Q2 2026 results moving from net losses to net income of $13.23M, and half-year net income of $69.29M. The company also completed a buyback of 843,187 shares for $9.87M under its Dec 2025 program and expanded its board to nine, adding Joseph Schocken. The article cites an ESOP-related $142.67M shelf registration and forecasts to 2029.
6 min readOmeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.
5 min readOMEROS CORP (OMER) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 12, 2026, the Board of Directors of Omeros Corporation (the “Company” or “we”), upon recommendation of the Nomina
2 min readInvesting.com reports market movers as S&P hits a record high amid softer PPI and rate-hike bets. Accelerant Holdings surged 43.2% on an all-cash buyout by Thoma Bravo at $20.25 per share. Omeros rose 24.5% after Q2 results beat expectations, including first positive operating cash flow. Other gainers include BBB Foods and ERock.
6 min readThe article lists Thursday premarket movers, citing large early price swings in multiple stocks. Gainers include FGI Industries (FGI) up 91% to $9.24, Accelerant Holdings (ARX) up 45% to $19.67, and Harmonic (HLIT) up 23% to $14.74. Losers include Cellebrite DI (CLBT) down 28% to $11.01 and Securitize (SECZ) down 21% to $6.25.
3 min readOmeros (OMER) shares rose about 17% in pre-open after the company reported Q2 2026 results. Adjusted EPS was $0.02 versus a consensus $0.25 loss, and revenue was $28.5M versus $12.67M expected. YARTEMLEA sales were $32.2M gross, and Omeros reported GAAP net income of $13.2M and first positive operating cash flow.
4 min readOMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Second Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 12, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second q
7 min read
